Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
HIV & AIDS
Do you routinely prescribe GLP-1 receptor agonists to people living with HIV (PLH) with obesity?
Nguyen Q, et al. PMID 38501237
Related Questions
What is your approach to a positive PPD or IGRA in a patient with well-controlled HIV without significant TB risk factors?
Do you treat patients with HIV-AIDS and positive cryptococcal antigenemia but negative CSF cryptococcal antigen with standard meningitis treatment given the potential for the postzone effect?
How do you counsel HIV patients with an undetectable viral load on breastfeeding?
How do you approach management for patient's with HIV on ART with persistent low level viremia but no new resistance mutations identified?
What is your approach to anal pap screening among MSM with HIV, and if routinely recommend, starting at what age (assuming access to HRA)?
How would you manage a patient with well controlled HIV on Biktarvy, who is interested in switching to injectable HAART but also has a history of a prior Hepatitis B Infection?
What is your approach when cryptococcus serum or CSF antigen titers do not change despite treatment in HIV-positive patients with cryptococcal meningitis or invasive disease, but there is clinical improvement and cultures remain negative?
Would you recommend starting a moderate-intensity statin in a patient under the age of 40 years old with HIV and a 10-year ASCVD risk estimate below 5%?
What are your top takeaways from ID Week 2024?
In what situations would you use "direct-to-inject" ART, such as Cabenuva, without an oral lead-in?
